INVO Bioscience, Inc. (INVO)
NASDAQ: INVO · IEX Real-Time Price · USD
0.931
0.00 (0.00%)
At close: May 3, 2024, 4:00 PM
0.925
-0.006 (-0.66%)
After-hours: May 3, 2024, 7:59 PM EDT

INVO Bioscience Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Cash & Equivalents
0.230.095.6810.11.240.210.030.150.49
Cash & Cash Equivalents
0.230.095.6810.11.240.210.030.150.49
Cash Growth
157.86%-98.41%-43.70%715.27%483.57%723.96%-83.10%-69.02%-
Receivables
0.140.080.050.020.010.230.0900
Inventory
0.260.260.290.270.10.040.060.090.07
Other Current Assets
0.620.190.280.160.20.250.060.010
Total Current Assets
1.260.626.3110.541.540.730.230.250.56
Property, Plant & Equipment
6.572.242.540.210.190.030.020.020
Long-Term Investments
3.091.241.490.100000
Goodwill and Intangibles
9.9700.130.090.060.010.020.020.02
Other Long-Term Assets
000000000
Total Long-Term Assets
19.633.484.160.40.250.050.030.030.02
Total Assets
20.894.110.4710.951.80.780.270.290.58
Accounts Payable
2.331.350.440.330.370.570.960.971.03
Deferred Revenue
0.410.120.013.574.290.02000
Current Debt
1.510.7600.690.020.40.210.220.22
Other Current Liabilities
3.971.180.8-2.31-3.182.523.963.583.09
Total Current Liabilities
8.223.411.252.291.53.55.134.774.34
Long-Term Debt
6.781.671.90.060.4400.130.130
Other Long-Term Liabilities
5002.863.570000
Total Long-Term Liabilities
11.781.671.92.924.0100.130.130
Total Liabilities
19.995.083.165.25.513.55.264.94.34
Total Debt
8.292.431.90.750.460.40.340.350.22
Debt Growth
240.62%27.93%152.76%64.45%15.64%15.46%-2.84%59.63%-
Retained Earnings
-57.82-49.78-38.89-32.24-23.89-21.72-18.65-17.94-15.82
Shareholders' Equity
0.89-0.987.315.74-3.71-2.72-4.99-4.62-3.76
Net Cash / Debt
-8.05-2.343.789.350.78-0.18-0.32-0.20.27
Net Cash / Debt Growth
---59.52%1096.42%-----
Net Cash Per Share
-5.14-3.867.1234.053.22-0.80-1.44-0.921.35
Working Capital
-6.96-2.795.058.250.04-2.77-4.89-4.52-3.78
Book Value Per Share
0.57-1.6113.7520.92-15.30-11.83-22.61-21.23-18.70
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).